SCHEMBL6912399

SCHEMBL6912399

CNCc1cc(Br)ccc1F

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 11/20 0.45
KCNH2 Q12809 8/20 0.45
HTR2A P28223 8/20 0.45
HRH3 Q9Y5N1 1/20 0.45
BRD4 O60885 1/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
BRDT Q58F21 1/20 0.43
MCL1 Q07820 1/20 0.40
SLC6A2 P23975 1/20 0.40
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
DPP4 P27487 1/20 0.37
PYCR1 P32322 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18839297 0.84 KDM1A (0.48) SLC6A4KCNH2HTR2AHRH3PYCR1
SCHEMBL26985827 0.81 CCR5 (0.51) BRD4BRD2BRD3BRDTDPP4
SCHEMBL10209952 0.80 BRD4 (0.37) SLC6A4KCNH2HTR2ABRD4BRD2
SCHEMBL3127209 0.79 SLC6A4 (0.54) SLC6A4KCNH2HTR2AMCL1SLC6A2
SCHEMBL18719608 0.79 SLC6A4 (0.47) SLC6A4KCNH2HTR2AHRH3SLC6A2
SCHEMBL26953015 0.79 BRD4 (0.35) SLC6A4KCNH2HTR2AHRH3BRD4
SCHEMBL13535945 0.78 USP28 (0.44)
SCHEMBL6911962 0.78 SLC6A4 (0.46) SLC6A4KCNH2HTR2AHRH3SLC6A2
SCHEMBL18588940 0.78 SLC6A4 (0.55) SLC6A4KCNH2HTR2ASLC6A2
SCHEMBL31163135 0.78 SLC6A4 (0.46) SLC6A4KCNH2HTR2AHRH3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
CN-119816491-A New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2025-04-11 CN disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 WO disclosed
EP-1112998-B1 AMINE DERIVATIVES POLA CHEM IND INC (JP) 2004-12-08 EP disclosed
US-6586633-B1 Antifungal agents POLA CHEMICAL INDUSTRIES, INC. (JP) 2003-07-01 US disclosed
EP-1112998-A1 AMINE DERIVATIVES POLA CHEMICAL INDUSTRIES, INC. (JP) 2001-07-04 EP disclosed
US-6245761-B1 NERVOUS SYSTEM, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS ELI LILLY AND COMPANY 2001-06-12 US disclosed
EP-0789688-A4 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS LILLY CO ELI (US) 1997-11-19 EP disclosed
EP-0789688-A1 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-08-20 EP disclosed
WO-1997009308-A1 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX SLC6A4 4850/4885KCNH2 3343/4885HTR2A 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.